- Capital Cube•8 months ago
Click here to see latest analysisEnervit SpA reports financial results for the year ended December 31, 2015.HighlightsGross margins widened from 42.39% to 45.99% compared to the same period last year, operating (EBITDA) margins now 5.48% from 8.58%.Change in operating cash flow of -73.37% compared to same period last year is about the same as change […] (Read more...) The post Enervit SpA :ENV-IT: Earnings Analysis: 2015 By the Numbers appeared first on CapitalCube.
- Capital Cube•last year
Click here to see latest analysisCapitalcube gives Enervit SpA a score of 78.Our analysis is based on comparing Enervit SpA with the following peers – Pierrel S.p.A., MolMed S.p.A., COSMO Pharmaceuticals S.A., Recordati S.p.A. and Newron Pharmaceuticals S.p.A. (PRL-IT, MLM-IT, COPN-CH, REC-IT and NWRN-CH).Investment OutlookEnervit SpA has a fundamental score of 78 and has a […] (Read more...) The post Enervit SpA – Value Analysis (MILAN:ENV) : December 24, 2015 appeared first on CapitalCube.
We're sorry this is all we were able to find about this topic.
ENV.MI : Summary for ENERVIT - Yahoo Finance
Enervit S.p.A. (ENV.MI)
Milan - Milan Delayed Price. Currency in EUR
Add to watchlist
|Day's Range||2.52 - 2.72|
|52 Week Range||1.97 - 3.19|
|PE Ratio (TTM)||56.58|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|